Stocks
Equillium, Inc.EQ
NASDAQHealthcareBiotechnology$2.11+19.32%
Price as of · delayed, not real-time
Focused on developing novel therapeutics for severe autoimmune and inflammatory disorders, Equillium is a clinical-stage biopharmaceutical company. Investors monitor its pipeline, particularly lead candidate itolizumab, for potential in treating conditions like acute graft-versus-host disease.
Market Cap: $87.7M52W Range: $0.76-$3.54
Congressional Interest in Equillium, Inc. (EQ)
8 members of Congress have disclosed 9 trades in Equillium, Inc. (EQ), a Healthcare company. The buy/sell breakdown shows 5 purchases versus 4 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
9
Unique Politicians
8
Buys
5
Sells
4
Who in Congress Is Trading EQ?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-12-14 | MICHAEL T. MCCAUL | buy | $1K-$15K |
| 2010-08-06 | BILLY LONG | sell | $15K-$50K |
| 2009-05-03 | CAROLYN MCCARTHY | buy | $603.09 |
| 2009-05-03 | CAROLYN MCCARTHY | buy | $603.09 |
| 2008-11-11 | THOMAS E. PETRI | sell | $15K-$50K |
| 2008-07-05 | David P. Roe | sell | $3,742.29 |
| 2008-01-08 | Lamar Smith | buy | $659.60 |
| 2007-10-07 | Vern Buchanan | buy | $1K-$15K |
| 2006-08-07 | David Scott | sell | $1K-$15K |